Simcha Therapeutics Announces the Opening of Two Clinical Studies Exploring ST-067 in Hematological Indications
Studies will assess ST-067 in acute myeloid leukemia or myelodysplastic syndrome and in multiple myeloma
Preclinical data to be presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition support the potential therapeutic use of ST-067 in hematologic cancers
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.–(BUSINESS WIRE)–Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the opening of two clinical studies assessing the use of ST-067, Simcha’s decoy-resistant IL-18, in hematological indications. One study (ClinicalTrials.gov ID NCT06492707) will assess ST-067 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), while the other study (ClinicalTrials.gov ID NCT06588660) will test ST-067 in combination with teclistamab (TECVAYLI®) in patients with multiple myeloma.
“These two studies, both of which may rapidly generate clinical proof-of-concept data in indications where there is significant need for better therapies, represent a very exciting opportunity for us to explore additional therapeutic areas that have great potential to respond well to treatment with IL-18,” said Sanuj Ravindran, M.D., chief executive officer of Simcha. “Emerging data, including those included in our preclinical poster to be presented at ASH, are generating signals that serve as proof-of-concept and point to the therapeutic potential of IL-18 across various hematological cancers, so we are pleased to partner with leading hematologic cancer experts on these trials.”
The AML/MDS study, under principal investigator Elizabeth Krakow, M.D., of Fred Hutch Cancer Center, is enrolling patients over 18 years of age who have persistent or recurrent AML or MDS after hematopoietic cell transplantation (HCT), also known as a bone marrow transplant
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?